Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:06:14.318Z.
Consensus retrieved: 2026-10-06T09:08:29.970Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:06:14.318Z.
Quote observation: 2026-10-06T16:05:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a5b8a39003d923715743cc0d1a2c59dcf36f227505f31b08d3d275f4059bcabd
Forward PE Ratio (N/A) = Dated Quote Price ($18.10) / Consensus Forward EPS ($-4.06)
FORWARD PE RATIO
N/A
Attovia Therapeutics, Inc.
Market Cap
$778.84M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | $778.84M | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $779.56M | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $774.02M | N/A |
| Geron Corporation (GERN)vs › | $792.28M | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $765.17M | N/A |
| AdaptHealth Corp. (AHCO)vs › | $795.92M | N/A |
| Apnimed, Inc. (APMD)vs › | $800.84M | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $802.16M | N/A |
| InMode Ltd. (INMD)vs › | $804.44M | 10.80 |
| Candel Therapeutics, Inc. (CADL)vs › | $746.62M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $18.10, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-4.06 | $-4.31 – $-3.93 | 1 | n/m |
| 2027-12-31 | $-2.38 | $-2.53 – $-2.31 | 2 | n/m |
| 2028-12-31 | $-2.44 | $-2.74 – $-2.09 | 3 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
